Medigus: Polyrizon’s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays
August 27 2021 - 7:30AM
Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in
advanced medical solutions, innovative internet technologies and
electric vehicle and charging solutions, today announced that
Polyrizon Ltd., a privately held company which Medigus owns 35.86%
of its share capital, presented pre-clinical data showing that its
Capture and Contain (C&C™) platform technology has the
potential to reduce the risk of an infection with Influenza virus
H1N1 and may potentially also treat additional Cold viruses.
Data from Polyrizon’s cell-culture study
confirms that its innovative product works in a dose-dependent
manner to effectively reduce the infection of cells from the
influenza virus H1N1, a subtype of influenza A virus (a
communicable viral disease), which causes upper, and potentially,
lower respiratory tract infections in the host it infects,
resulting in symptoms such as nasal secretions, chills, fever,
decreased appetite, and possibly lower respiratory tract
disease.
Polyrizon tested several formulations of its
lead platform against Influenza virus H1N1. In these studies, the
products candidates demonstrated high efficacy by preventing
the influenza virus from affecting epithelial host cells and
inhibit cells death.
Polyrizon’s new product candidate protects the
nasal cavity and the respiratory tract and by that preventing the
virus from colonizing in the upper respiratory and may decrease the
viral load and facilitate the immune system to control the virus
more effectively.
Polyrizon’s product candidate showed a promising
safety profile in a cell toxicity studies, together with broad
spectrum activity against different viruses as demonstrated in
previous study against human corona virus 229E.
These pre-clinical data highlight the Capture
and Contain (C&C™) impact of Polyrizon’s product line that can
be extended against Flu and Cold viruses and a variety of different
respiratory viruses.
About Medigus
Medigus is traded on the Nasdaq Capital Market.
To learn more about the company’s advanced technology, please
visit http://www.medigus.com/investor-relations
Cautionary Note Regarding Forward Looking
Statements
This press release may contain statements that
are “Forward-Looking Statements,” which are based upon the current
estimates, assumptions and expectations of Medigus’ management and
its knowledge of the relevant market. The company has tried, where
possible, to identify such information and statements by using
words such as “anticipate,” “believe,” “envision,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,”
“contemplate” and other similar expressions and derivations thereof
in connection with any discussion of future events, trends or
prospects or future operating or financial performance, although
not all forward-looking statements contain these identifying words.
For example, Medigus uses forward looking statements when
describing conclusions from Polyrizon’s pre-clinical study, the
influence of Polyrizon’s product candidate on the viral load and
the immune system, the product candidate’s safety profile and its
preventative effect. These forward-looking statements represent
Medigus’ expectations or beliefs concerning future events, and it
is possible that the results described in this press release will
not be achieved. By their nature, Forward-Looking Statements
involve known and unknown risks, uncertainties and other factors
which may cause future results of the Medigus’ activity to differ
significantly from the content and implications of such statements.
Other risk factors affecting Medigus and Polyrizon are discussed in
detail in the Medigus’ filings with the Securities and Exchange
Commission. Forward-Looking Statements are pertinent only as of the
date on which they are made, and Medigus undertakes no obligation
to update or revise any Forward-Looking Statements, whether as a
result of new information, future developments or otherwise.
Neither Medigus nor its shareholders, officers and employees, shall
be liable for any action and the results of any action taken by any
person based on the information contained herein, including without
limitation the purchase or sale of Medigus’ securities. Nothing in
this press release should be deemed to be medical or other advice
of any kind
Contact (for media only)
Tali DinarChief Financial
Officer+972-8-6466-880ir@medigus.com
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Apr 2023 to Apr 2024